DDInter1073 DDInter1840
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Linezolid {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Linezolid {u} (Compound) upregulates {v} (Gene) ZFP36
ZFP36 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) interacts with {v} (Gene) and {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Linezolid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Linezolid (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid (Compound) downregulates IER3 (Gene) and IER3 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Linezolid (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) interacts with SRC (Gene) and NFKBIA (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds SRC (Gene) and Crizotinib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Trabectedin (Compound)